Haleon reportedly evaluating sale of certain smoking cessation products
The business could be worth as much as $800 million.
Haleon, the consumer health unit spun off from GSK last year, is reportedly evaluating the possible sale of some of its smoking cessation products, according to a Bloomberg report.
Haleon is working with an adviser to find potential bidders for the Nicotine brand of nicotine gum, patches and lozenges, according to the report, which cited people familiar with the matter.
The business could be worth as much as $800 million, the report noted.
[Read more: GSK formally debuts Haleon consumer business]
In February, Bloomberg reported that Haleon was evaluating a sale of its ChapStick lip balm brand.
[Read more: GlaxoSmithKline to spin off Haleon consumer business in July]